EUSense

Company Overview

Snapshot

Founded in July 2024 by Tamar Rucham, EUSense operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its patent-pending AI technology for GI cancer diagnosis and treatment. However, EUSense ceased operations in December 2025.

Business overview

EUSense is a Health Tech & Life Sciences company leveraging artificial intelligence to enhance the diagnosis and treatment of GI cancer using endoscopic ultrasound (EUS). The company's core technology is a patent-pending AI designed to detect pancreatic abnormalities and classify malignancies, aiming to make advanced EUS procedures more accessible and accurate. EUSense targets the healthcare sector, specifically GI clinics, to enable broader adoption of advanced treatments for patients worldwide.

Company Intelligence Q&A

What is EUSense's primary focus?

EUSense is focused on transforming GI cancer diagnosis and treatment through AI-powered endoscopic ultrasound, aiming to improve accessibility and accuracy of advanced procedures.

When was EUSense founded and by whom?

EUSense was founded in July 2024 by Tamar Rucham.

What is the status of EUSense's operations?

EUSense ceased operations in December 2025.

What is the core technology developed by EUSense?

EUSense has developed a patent-pending AI that excels at detecting pancreatic abnormalities and shows promising results in malignancy classification for endoscopic ultrasound procedures.

Which markets does EUSense aim to serve?

EUSense aims to serve the healthcare market, specifically GI clinics, to enable more widespread access to advanced cancer treatments globally.